

### **CADTH REIMBURSEMENT REVIEW**

# Stakeholder Feedback on Draft Recommendation

remdesivir (Veklury)

(Gilead Sciences Canada, Inc.)

**Indication:** Hospitalized patients 12 years of age (weighing at least 40 kg) with pneumonia requiring supplemental oxygen.

August 1, 2024

**Disclaimer:** The views expressed in this submission are those of the submitting organization or individual. As such, they are independent of CADTH and do not necessarily represent or reflect the view of CADTH. No endorsement by CADTH is intended or should be inferred.

By filing with CADTH, the submitting organization or individual agrees to the full disclosure of the information. CADTH does not edit the content of the submissions.

CADTH does use reasonable care to prevent disclosure of personal information in posted material; however, it is ultimately the submitter's responsibility to ensure no identifying personal information or personal health information is included in the submission. The name of the submitting stakeholder group and all conflicts of interest information from individuals who contributed to the content are included in the posted submission.

### **CADTH Reimbursement Review**

## **Feedback on Draft Recommendation**

Stakeholder information	
CADTH project number	SR0833
Name of the drug and	remdesivir (Veklury)
Indication(s)	
Organization Providing	
Feedback	

1. Recommendation revisions Please indicate if the stakeholder requires the expert review committee to reconsider or clarify its recommendation.			
Request for Reconsideration	<b>Major revisions:</b> A change in recommendation <b>category</b> or patient <b>population</b> is requested		
	Minor revisions: A change in reimbursement conditions is requested		
No Request for Reconsideration	<b>Editorial revisions:</b> Clarifications in recommendation <b>text</b> are requested		
	No requested revisions	Х	

# **2.** Change in recommendation category or conditions Complete this section if major or minor revisions are requested

Please identify the specific text from the recommendation and provide a rationale for requesting a change in recommendation.

### 3. Clarity of the recommendation

Complete this section if editorial revisions are requested for the following elements

#### a) Recommendation rationale

Please provide details regarding the information that requires clarification.

### b) Reimbursement conditions and related reasons

Please provide details regarding the information that requires clarification.

### c) Implementation guidance

Please provide high-level details regarding the information that requires clarification. You can provide specific comments in the draft recommendation found in the next section. Additional implementation questions can be raised here.